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It is becoming more evident that histone acetylation, as one of the epigenetic modifications 
or markers, plays a key role in the etiology of Alzheimer’s disease (AD). Histone acetylases 
and histone deacetylases (HDACs) are the well-known covalent enzymes that modify the 
reversible acetylation of lysine residues in histone amino-terminal domains. In AD, however, 
the roles of these enzymes are controversial. Some recent studies indicate that HDAC 
inhibitors are neuroprotective by regulating memory and synaptic dysfunctions in cellular 
and animal models of AD; while on the other hand, increase of histone acetylation have 
been implicated in AD pathology. In this review, we focus on the recent advances on the 
roles of histone acetylation covalent enzymes in AD and discuss how targeting these 
enzymes can ultimately lead to therapeutic approaches for treating AD.
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introduction to Alzheimer’s Disease
Alzheimer’s disease (AD) is well known for the symptom of progressive memory loss. It is the most 
common neurodegenerative disease in the elderly, with an estimated 10–30% prevalence by age 85 or 
older and a 6–8% incidence in the same age group (Mayeux, 2003). Pathologically, AD is characterized 
by amyloid plaques and neurofibrillary tangles in select brain regions, including the temporal and 
parietal lobes, and in restricted regions within the frontal cortex and cingulate gyrus (Mattson, 2004; 
Tanzi and Bertram, 2005). The amyloid plaques are extracellular deposits of neurotoxic amyloid-β 
(Aβ) 40–42 peptides, highly involved in synaptic dysfunction and neuron death. Neurofibrillary 
tangles are intracellular accumulations of hyperphosphorylated tau, a microtubule-associated protein 
involved in the promotion and stabilization of microtubules (Ballatore et al., 2007). The “plaques” 
and “tangles” play a critical role in the oxidative stress damage, energy metabolism disturbance, and 
abnormal cellular calcium homeostasis, and hence increase the risk for developing AD (Mattson, 2004).
There are more and more genetic factors found to be strongly implicated for causing or increasing 
the risk of AD development. In the identification of familial AD (FAD) genes, mutations in the 
presenilin 1 (PS1) gene are the most frequent (81%), followed by amyloid precursor protein (APP) 
(14%), making PS1 variation as the well-known genetic cause of FAD (http://www.molgen.ua.ac.
be/ADMutations). PS1 is the catalytic core component of γ-secretase, one of the sequential cleavage 
enzymes to APP, and mainly produces the neurotoxic Aβ peptides that are responsible for neuronal 
degeneration and cognitive dysfunction in AD (Scheuner et al., 1996). In clinics, the majority of AD 
cases are sporadic without any linkage to family history. The apolipoprotein E (APOE) ε4 allele has 
been linked to high susceptibility to developing sporadic AD (SAD), and the presence of an APOE 
ε4 allele is also associated with amyloidogenic processing and neurofibrillary tangles (Roses, 1997).
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The complex pathogenetic background of AD implies that 
both genetic and non-genetic factors are possible causes in the 
diverse signaling pathways leading to AD. There is a multitude 
of environmental factors, for example, physical exercise, diet, 
cognitive training, education level, and head trauma, that may 
play a role in the development of AD. However, the research 
regarding environment and gene-environment interactions has 
not matured enough to yield a clear picture about AD (Young 
et al., 1999; Cotman and Berchtold, 2002; Mattson, 2003; Mayeux, 
2003; Ngandu et al., 2015).
Histone and Non-Histone Acetylation and 
Alzheimer’s Disease
Epigenetic processes integrate abundant signals of genetics and 
environment into phenotypic outcomes. They are considered herit-
able alterations in gene expression without any changes in their 
coding sequence (Egger et al., 2004). Such epigenetic processes 
include histone modifications (acetylation, phosphorylation, 
methylation, ubiquitination, ADP ribosylation, and sumoylation), 
DNA methylation, and non-coding RNAs (Goldberg et al., 2007). 
Histone acetylation and deacetylation regulate gene transcription 
by altering the chromatin structure and the accessibility to tran-
scription factors. The alkaline histones are abundantly found in 
eukaryotic cell nuclei and they are chief protein components of 
chromatin. They form octamers that wrap around DNA to form 
nucleosomes, and each histone octamer consists of two distinct 
copies of the four core histones (H2A, H2B, H3, and H4). Histone 
H3 and H4 acetylation have been demonstrated to be markers of an 
“open” configuration of chromatin. Core histones are acetylated on 
lysine residues at the N-terminal tails and facilitate gene transcrip-
tion by neutralizing the positive charge of histone tails and reduc-
ing the binding of histone to negatively charged DNA (Kouzarides, 
2007). In general, histone acetylation is closely associated with 
gene transcriptional activation, while histone deacetylation usually 
leads to gene transcriptional repression (Figure 1).
Dysregulation of histone acetylation is involved in a variety 
of signal transduction pathways such as cell differentiation, cell 
apoptosis, vascular remodeling, inflammation reaction, immune 
responses, neuronal plasticity, and metabolic reprograming 
(Powell et al., 1999; Barnes, 2009; Keenen and de la Serna, 2009; 
Pons et al., 2009; Witt et al., 2009; Graff et al., 2012; Mihaylova and 
Shaw, 2013). Altered acetylation of both nuclear and cytoplasmic 
non-histone proteins has also been associated with AD, including 
NF-κB (Chen et al., 2001), p53 (Barlev et al., 2001), alpha tubulin 
(Perez et al., 2009), and tau (Min et al., 2010; Irwin et al., 2012), 
adding another level of regulation to molecular pathways in AD.
Acetylases p300/CBP acetylate multiple lysine residues of 
NF-κB, including Lys-122, -123, -218, -221, and -310 (Chen et al., 
2001). Park et al. found that PCAF (p300/CBP associated factor) 
selectively acetylates the Aβ-induced activation of NF-κB at Lys-
122 by the Western blot using an antibody against acetyl-NF-κB 
(K122), while on the other hand, the PCAF inhibitor C-30-27 
selectively inhibits acetylation-dependent NF-κB at Lys-122 and 
suppresses the NF-κB-mediated inflammatory response induced 
by Aβ in both BV2 and Neuro-2A cells (Park et al., 2013, 2015). 
However, HDAC inhibitor valproic acid (VPA) also decreases the 
mRNA levels of NF-κB in both plasma and hippocampus of Tg6799 
AD mice (Noh and Seo, 2014). These discordant results suggest 
that the acetylation-induced regulation of NF-κB expression in 
AD pathology needs more clarification and research. Furthermore, 
NF-κB is also tightly regulated by another deacetylase sirtuin SIRT1 
in AD in vitro models (Chen et al., 2005; Marwarha et al., 2014).
The tumor suppressor and transcription factor p53 is modified 
by acetylation, which does not increase DNA binding of p53 but 
promotes coactivator recruitment and histone acetylation (Barlev 
et al., 2001). One research team found that acetylations of p53 
are significantly increased in AD brain tissue, and p300 activities 
might converge to increase p53 levels in AD brains by inducing 
p53 acetylation in its C-terminal domain (Aubry et al., 2015). It has 
also been suggested that CBP/p300 induced p53 hyperacetylation 
is enriched during neuronal outgrowth and maturation (Tedeschi 
et al., 2009). For the HDAC, SIRT1 agonist resveratrol decreases 
the acetylation of p53 and hence rescues increased p53 acetylation 
in the CK-p25 model of neurodegeneration (Kim et al., 2007).
It is known that tau is acetylated in neurodegeneration and 
that tau acetylation suppresses degradation of phosphoryl-
ated tau (p-tau). Histone acetyltransferase p300 regulates the 
tau acetylation and the deacetylase SIRT1 mediates the tau 
deacetylation (Min et al., 2010). Irwin et al. also observed the 
acetylated-tau pathology in a spatial distribution pattern similar 
FiGURe 1 | Histone acetylases (HATs) reversibly transfer the acetyl 
groups to the core histones by neutralizing the positive charge of the 
lysine (K) residues in histone N-terminals, resulting in an open 
chromatin structure accessible to transcriptional factors and an 
activation of gene transcription, while histone deacetylation usually 
leads to gene transcriptional repression.
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to hyperphosphorylated-tau. They detected the acetylated-tau 
at lysine 280 in AD and showed that acetylated-tau pathology 
is largely intracellular and present throughout all stages of AD 
progress, especially moderate- to severe-stage cases. The acety-
lated-tau may contribute to tau-mediated neurodegeneration by 
reducing solubility and microtubule assembly and increasing tau 
fibrillization (Irwin et al., 2012). CREB-binding protein (CBP) 
acetylates tau at Lys280 within the tau microtubule-binding 
motif, and that acetylation of tau possibly leads to increased tau 
aggregation (Cohen et al., 2011). Tau acetylation also correlates 
with the concentration of p300; however, p300 and CBP may 
preferentially acetylate different residues in tau, thus differentially 
affecting tau’s intrinsic propensity to aggregate (Cook et  al., 
2014a,b). Reversely, HDAC6 activity presumably enhances the 
deacetylation of both tubulin and tau, which may contribute to 
tau-microtubule interactions and microtubule stability (Cook 
et al., 2014a,b).
The discovery of the association of the impairment of histone 
acetylation homeostasis with the memory deficit during the past 
10 years brought about a rapid increase in the knowledge of cog-
nitive dysfunction of neurodegenerative disorders. Acetylation 
of the hippocampal histones (H2B, H3, and H4) are transiently 
increased in normal mice during learning processes, suggesting 
that histone acetylation is essential for memory consolidation 
(Levenson et al., 2004; Levenson and Sweatt, 2005; Fischer et al., 
2007; Koshibu et al., 2009; Peleg et al., 2010). Gjoneska et al. not 
only found decreased H3K27 acetylation at regulatory regions of 
synaptic plasticity genes in the p25 transgenic model of AD but 
also found increased H3K27 acetylation at regulatory regions of 
immune response genes. These changes in histone acetylation 
correspond to the changes in transcription (Gjoneska et  al., 
2015). While histone acetylation shows an overall decrease in 
the aged mice, the application of HDAC inhibitors reverses 
such decreases in the global histone acetylation and improves 
the memory deficits in vivo (Chuang et al., 2009; Graff et al., 
2012; Walker et al., 2012). However, some studies found that 
histones are hyperacetylated in neuroblastoma cells by Aβ 
peptide deposits (Guo et  al., 2011; Gu et  al., 2013; Lu et  al., 
2014). It is reported that some APP metabolism related genes 
are also regulated by histone acetylation. In our previous stud-
ies, we found that H3 in the promoters of PS1 and BACE1, a 
β-secretase to APP for Aβ peptides, is hyperacetylated in N2a 
cells transfected with Swedish mutated APP (Lu et al., 2014). 
Similar H3 hyperacetylation of BACE1 promoters has been 
reported in APP/PS1/tau triple transgenic mice (Marques et al., 
2012). Nevertheless, neprilysin (NEP), a major degrader of Aβ 
peptides, is downregulated due to the decreased H3 acetyla-
tion at the gene promoter regions in hypoxia stimulated mouse 
cortical and hippocampal neurons (Wang et al., 2011). These 
discordant results indicated that the role of histone acetylation 
abnormality in AD pathology is still unclear, and a thorough 
understanding of these issues would likely lead to the develop-
ment of effective treatments for AD.
Histone Deacetylase and Alzheimer’s Disease
Generally, histone deacetylases (HDACs) repress transcription by 
removing an acetyl group from the histone tail and compacting 
chromatin. Mammalian HDAC enzymes are classified into four 
major categories in line with their homology to yeast: (1) Class I 
HDACs consist of HDACs 1, 2, 3, 8; (2) Class II HDACs further 
separate into two subclasses, class IIa including HDACs 4, 5, 7, 
9 and class IIb HDACs 6, 10; (3) Class III HDACs are named as 
sirtuins and include SirT1-7, sharing their homology sequence 
to the yeast Sir2; and (4) Class IV HDACs include only HDAC11 
(Chuang et al., 2009). Class I, II, and IV HDACs are zinc-dependent 
enzymes, while Class III HDACs enzymes are dependent on 
nicotinamide adenine dinucleotide (NAD+).
HDAC2 is widely expressed in the central nervous system and 
negatively regulates memory and synaptic plasticity. The hip-
pocampi of HDAC2-overexpressing mice showed hypoacetylation 
of histone H4 on lysines 12 and 5 (H4K12, H4K5) but not H3K14, 
accompanied by decreased synapse number and synaptic plastic-
ity, resulting in impaired memory formation. The mechanism is 
believed to be via the binding of HDAC2 to the promoters of 
synaptic-plasticity-related genes and thereby negatively regulates 
their transcriptions (Guan et  al., 2009). HDAC2 expression is 
increased in the post-mortem brain samples of AD patients. 
Knocking down HDAC2 by short-hairpin-RNA restores the 
structural synaptic plasticity and memory impairments in CK-p25 
mice by the way of HDAC2 reversely regulating H4K12 acetyla-
tion of the memory related gene promoters (Graff et al., 2012). 
These findings underline the important role of HDAC2-regulated 
chromatin modification in regulating the synaptic plasticity and 
memory formation in the cognitive impairment context of AD.
An increased HDAC6 protein level is observed in the cortices 
and hippocampi of AD postmortem brain samples (Ding et al., 
2008), and reducing endogenous HDAC6 restores the learning and 
memory deficits and α-tubulin acetylation in an AD mouse model 
(Govindarajan et al., 2013). It is believed that cytoplasmic deacety-
lase HDAC6 participates in tau metabolism, one pivotal process 
involved in neurofibrillary tangles in AD (Ding et al., 2008). On one 
hand, HDAC6 levels positively correlate with the tau burden, and 
a decrease in HDAC6 activity or expression significantly prevents 
tau aggregation and accelerates tau clearance via acetylation of tau 
on KXGS motifs (Cook et al., 2012, 2014a,b). Conversely, tau can 
also function as an inhibitor of HDAC6, and overexpression of 
tau corresponds with tubulin hyperacetylation (Perez et al., 2009). 
On the other hand, an inhibitor of HDAC6-mediated α-tubulin 
deacetylation, tubacin represses tau phosphorylation at T231, a 
critical tau function site (Ding et  al., 2008), and decreases cell 
motility without affecting the stability of microtubules (Haggarty 
et al., 2003). Moreover, inhibition of HDAC6 activity also blocks 
mitochondrial lengthening and transportation in Aβ-induced 
hippocampal neurons, perhaps in a GSK3β-dependent manner 
(Chen et al., 2010; Kim et al., 2012).
Sirtuins are well known for their association with human lon-
gevity and their potential ability to delay the onset of age-related 
AD. AD patients have shown a significant reduction of SIRT1 
expression in the parietal cortex, but not in the cerebellum, which is 
at par with their severity of cognitive impairment. Further analyses 
confirm that the cortical SIRT1 loss is negatively associated with 
the accumulation of Aβ and tau. However, the reduction of SIRT1 
is not found in APP/PS1/tau triple-transgenic animals (Julien et al., 
2009). In p25 transgenic mouse, another model of AD, increasing 
TABLe 1 | HDAC family and HDAC inhibitors.
HDAC subclass Localization Selective-
inhibitor
Non-selective-
inhibitor
Class I 
zinc-dependent
HDAC1 Nucleus MS-275, 
FK-228
TSA, VPA
HDAC2 Nucleus FK-228, 
Apician
Butyrate, SAHA
HDAC3 Nucleus, 
cytoplasm 
Apician, 
RGFP136
MGCD0103
HDAC8 Nucleus, 
cytoplasm
Class Iia 
zinc-dependent
HDAC4 Nucleus, 
cytoplasm
TSA, phenyl 
butyrate
HDAC5 Nucleus, 
cytoplasm
HDAC7 Nucleus, 
cytoplasm
HDAC9 Nucleus, 
cytoplasm
Class Iib 
zinc-dependent
HDAC6 Cytoplasm Tubacin TSA, SAHA
HDAC10 Nucleus, 
cytoplasm
Class III 
NAD+-dependent
SirT1 Nucleus Suramin Nicotinamide
SirT2 Nucleus, 
cytoplasm
Suramin, 
AGK2
SirT3 Mitochondria
SirT4 Mitochondria
SirT5 Mitochondria
SirT6 Nucleus
SirT7 Nucleus
Class IV 
zinc-dependent
HDAC11 Nucleus
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SIRT1 activity reduces neurodegeneration in the hippocampus. 
SIRT1 agonist resveratrol decreases the acetylation of the SIRT1 
substrates PGC-1α and p53 and prevents the learning impairment 
(Kim et al., 2007). Meanwhile, SIRT1 mediates synaptic plasticity 
and memory formation via modulation of miR-134 expression 
(Gao et al., 2010). Sirtuin SIRT1 also tightly regulates NF-κB activ-
ity in AD progression. Chen et al. discovered that SIRT1 reduces 
Aβ-induced toxicity by inhibiting NF-κB signaling, and SIRT1 
overexpression suppresses the Aβ-dependent NF-κB activation, 
blocking the neuropathogenic inflammatory reaction in primary 
neurons (Chen et  al., 2005). On the other hand, inhibition of 
SIRT1 induces an increase of NF-kB reporter activity and BACE1 
promoter activity, but SIRT1 inhibitor sirtinol does not change 
the binding of NF-κB in the BACE1 promoter region (Marwarha 
et al., 2014). Far-ranging functions of SIRT1 have been explored 
in the pathogenesis of aging and neurodegeneration, raising the 
possibility for its use in therapeutic interventions for AD.
HDAC inhibitors
The molecular and clinical implications of the HDAC inhibitors 
were initially identified in cancer therapy (Carew et  al., 2008). 
Notably, the HDAC inhibitors restores the learning and memory 
deficits in AD mouse models, especially in the early stage AD 
mouse cortex, making it a promising drug for AD (Fischer et al., 
2007; Vadnal et al., 2012). In fear-conditioned AD mouse models, 
the HDAC inhibitors such as trichostatin A (TSA), VPA, SAHA 
(vorinostat) or sodium butyrate increase the synapse remod-
eling and enhance the contextual memory by regulating H3/H4 
acetylation of relevant gene promoters to enhance hippocampal 
long-term potentiation (Fischer et al., 2007, 2010; Francis et al., 
2009; Guan et  al., 2009; Kilgore et  al., 2010; Ricobaraza et  al., 
2012). At the molecular level, sodium butyrate recruits acetylated 
H3/H4 to the DHCR24 enhancer and increases gene expression 
which is reduced in the temporal cortex of an AD patient’s brain 
(Drzewinska et al., 2011).
Nevertheless, most of the HDAC inhibitors are non-selective 
and target not only nuclear histones but also cytoplasmic non-
histone proteins. Some HDAC inhibitors such as TSA selectively 
regulate the expression of memory-related genes rather than 
globally alter gene expression in a non-specific manner (Vecsey 
et al., 2007). It is hence expected that certain structural features 
of the HDAC inhibitors are identified with conferring potency 
and specificity (Haggarty et al., 2004). Khan et al. compared the 
clinically relevant HDAC inhibitors against the rhHDAC (recom-
binant human HDAC) microforms and identified the potency and 
selectivity of ten microforms that increase histone acetylation in 
Hela cells (Khan et al., 2008). The microforms of these four groups 
of HDACs and main HDAC inhibitors are listed in Table 1.
The HDAC inhibitors regulate specific gene transcription 
not only by acetylating the histones of the gene promoter or 
enhancer directly but also by acetylating the genes relevant to the 
transcriptional regulator such as Sp1 and HNF4a indirectly (Ryu 
et al., 2003; Yang et al., 2009). Still, only 8–20% of all the genes 
analyzed display permissive conformations for transcription in 
cells with the HDAC inhibitors treatment. The HDAC inhibitors 
are likely to modulate transcriptional programs of certain relatively 
specific genes (Fischer et al., 2007).
Histone Acetylases and Alzheimer’s Disease
Histone acetylases (HATs), contrary to HDACs, are recruited 
to reversibly transfer acetyl groups to lysine residues of histone 
N-terminals, resulting in an open chromatin structure accessible 
to transcriptional factors. HATs are broadly divided into two main 
groups according to their cellular localization, the nuclear A-type 
HATs, and the cytoplasmic B-type HATs. A-type HATs share a 
highly conserved motif, including an Acetyl-CoA binding site, and 
mainly acetylate the histones of nuclear chromatin, which directly 
impacts activation of transcriptional responses. Conversely, B-type 
HATs acetylate the newly synthesized cytoplasmic histones, mak-
ing ample histones free to enter the nucleus. A-type group contains 
three primary subclasses of HATs based on structural homology in 
their primary sequences: (1) GNAT (Gcn5-related N-acetylases) 
family, containing human Gnc5, PCAF, and elongator complex 
protein 3(ELP3); (2) MYST family, comprised of Tip60, MOZ/
MYST3, MORF/MYST4, HBO1/MYST2, and HMOF/MYST1; 
and (3) p300/CBP family, represented by p300 and CBP (Roth 
et al., 2001). The groups of the HAT families are represented in 
Table 2.
Among the studies of HATs and their associations with AD 
development, Tip60 is most generally believed to be a valid thera-
peutic approach to slowing down or even stopping the dementia 
progression. Tip60 was initially discovered through its interaction 
with the HIV-1 transactivator protein Tat. Lorbeck et al. found 
that the HAT activity of Tip60 regulates neuronal-specific gene 
TABLe 2 | HAT family.
HAT subclass (type A) Histone substrate
GNAT family Gnc5, PCAF, ELP3 H3K9, 14, 18, 36
MYST family Tip60, MOZ, MORF, 
HBO1, HMOF
H4K5, 8, 12, 16, 
H3K14
p300/CBP family p300, CBP H2AK5, H2BK12, 15,  
H3K14, 18, H4K5, 8
Transcription factor related TFIIIC, TAF1 H3K9, 14, 18
Nuclear receptor co-activators SRC, ACTR, P160, 
CLOCK
H3/4
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profiles that are linked to the behavior, learning, and memory in 
Drosophila (Lorbeck et al., 2011). This group further proved that 
the activity of Tip60 controls the synaptic remodeling and structure 
in the Drosophila neuromuscular junction (Sarthi and Elefant, 
2011). They also pointed out that in the APP transgenic Drosophila, 
Tip60 HAT activity loss increases the APP transcriptional expres-
sion, which induces lethality and a neuronal apoptotic reaction 
(Pirooznia et al., 2012). These results suggest a key neuroprotective 
role of Tip60 HAT activity for AD neurodegenerative pathology 
in humans.
It was implicated that the loss of HAT activity in CBP/p300 
is related to the neuronal survival and long-term memory. The 
loss or over-expression of CBP/p300 are both responsible for the 
neuronal death, implying that only a fine-tuning of CBP HAT 
activity is neuroprotective in the context of AD development 
(Rouaux et al., 2003). Behavior-trained rats display an increase 
in the activity/expression of CBP/p300 and PCAF, accompanied 
by hyperacetylated H2B/H4 in the promoters of the synaptic-
plasticity-related genes (Bousiges et  al., 2010). Meanwhile, 
CBP-dependent transcriptional neuroadaptation is required for 
environmental enrichment-induced neurogenesis and cognitive 
enhancement (Lopez-Atalaya et  al., 2011). AD pathological 
contexts also show a critical CBP/p300 loss with histone H3 dea-
cetylation (Rouaux et al., 2003). Furthermore, CBP/p300 inhibitor 
EID1 has been successfully utilized to identify the protective 
role of CBP/p300 in the memory processes. Increase of EID1 
nuclear translocation induces a decline in the spatial learning 
and long-term potentiation in the hippocampus by reducing the 
neuronal structural protein βIII-tubulin expression (Liu et  al., 
2012), whereas the elimination of CBP does not affect the neuronal 
viability (Valor et al., 2011).
Nonetheless, the p300 acetyltransferase activity is upregulated 
and may interact with the hyperacetylation of tau in AD brains 
(Aubry et al., 2015). In the FAD pathology context, CBP/p300 
shows a negative role. PS1 mutations repress the proteasomal 
degradation of CBP/p300 and up-regulate the CREB-mediated 
gene transcription in murine neurons (Marambaud et al., 2003). 
In addition, PS1/2 knock-out mice reveal a decline in the CBP/
p300 expression (Saura et al., 2004). In our previous study, we 
also found that the Swedish APP mutation induces the p300 
expression up-regulation in N2a cells (Lu et  al., 2014). These 
ambiguous results point to the need for further studies on the 
HAT activity of epigenetic CBP/p300 functions in the develop-
ment of AD.
Some studies point out that enhancement of HAT activity, 
similar to the HDAC inhibitors in function, is another potential 
therapeutic approach for AD (Rouaux et al., 2003; Tedeschi et al., 
2009; Bousiges et al., 2010; Liu et al., 2012; Park et al., 2013, 2015). 
Compared to the VPA treatment, HAT activators CSP–CTPB 
injections potently induce the histone H2B acetylatation in the 
hippocampus (Selvi et al., 2010). The CREB-CBP transcriptional 
complex is also involved in the HDAC inhibitors treatment, induc-
ing the enhancement of the hippocampus-dependent memory and 
synaptic plasticity (Vecsey et al., 2007).
Therapeutic Perspectives
Accumulating evidences in  vivo and in  vitro support the 
contention that histone modification and dysfunction are 
associated with the etiology of AD. Experimental evidence 
suggests that HDAC inhibitors treatments, both ameliorate 
cognitive deficiencies, protect against memory impairment, 
promoting the possibility of their further development in 
clinical trials in AD patients. However, several intractable and 
complex issues remain and need to be addressed for further 
experimental and clinical applications. One of the most urgent 
issues is to effectively identify the isoform-specificity of the 
HDAC inhibitors, as non-selective HDAC inhibitors lead to 
a loss in the signal-non-specific responses. Despite animal 
experiments, pharmaceutical and clinical characteristics of an 
HDAC inhibitor treatment such as brain permeability, efficacy, 
toxicity, and distribution need to be further investigated in 
future randomized placebo-controlled clinical trials with a 
PK-PD and/or imaging component.
Although the protective role of the HDAC inhibitors in AD 
is widely known, the pattern of histone acetylation in the AD 
pathology is still not well understood. While the global histone 
acetylation is decreased in some AD animal and cellular models, 
the histone acetylation is either increased or decreased in some 
specific regions of certain genes that function disjointedly or in 
agreement. For example, the memory-related genes have histone 
hypoacetylation, resulting in low expression of these genes 
(Levenson et al., 2004; Levenson and Sweatt, 2005; Fischer et al., 
2007; Koshibu et al., 2009; Peleg et al., 2010). In our previous 
study, we found that the genes directly related to AD pathology 
such as PS1 and BACE1 are hyperacetylated, resulting in the 
high transcription of these genes (Lu et al., 2014). The global 
histone acetylation may be a result of varying degrees of histone 
acetylation modulation of various genes. Furthermore, it appears 
that not all histones impact memory formation. It is interesting 
to note that training or environmental enrichment can induce 
the acetylation of some specific histones. For example, it was 
observed that acetylation of histone H3 and H4 are increased in 
the hippocampus and cortex of p25 transgenic mice following 
environmental enrichment (Fischer et al., 2007). During learn-
ing, a specific deregulation of the histone H4 lysine 12 acetylation 
is observed in aged mice (Peleg et al., 2010). What is more, CBP/
p300 might affect the acetylation of specific histones/non-histone 
proteins in neurodegenerative disease. Elimination of CBP in the 
forebrain principal neurons preferentially reduced acetylation 
of histone H2A and H2B in Rubinstein-Taybi syndrome (Valor 
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et al., 2011). Increased amounts of EID1, an inhibitor of CBP/
p300, in hippocampal neurons significantly reduced the acetyla-
tion of H3 and p53, but not other histones (Liu et  al., 2012). 
Moreover, it is possible that the overall level of histone acetylation 
depends on different brain regions, animal models, cellular type, 
and gene regions (Graff and Mansuy, 2009). From this point of 
view, it is important to undertake a more global view to look at 
the mechanism of epigenetic modulation as a therapeutic target 
in AD. The chromatin modification of the AD-related genes needs 
further investigation in AD patients and in vivo or in vitro.
Nonetheless, there is no doubt that HDAC inhibition presents 
a novel promising avenue for the development of therapeutic 
strategies for Alzheimer disease and its associated learning and 
memory impairments. New insights of histone acetylation in the 
etiology of AD are awaiting further exploration, making previously 
irreversible brain disorders potentially reversible.
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